These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12106524)

  • 41. Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study.
    Small W; Milloy MJ; McNeil R; Maher L; Kerr T
    AIDS Res Ther; 2016; 13():26. PubMed ID: 27462360
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors and Evolution of Antiretroviral Therapy Adherence Among Perinatally HIV-Infected Adolescents in Brazil.
    Côté J; Delmas P; de Menezes Succi RC; Galano E; Auger P; Sylvain H; Colson S; Machado DM
    J Adolesc Health; 2016 Sep; 59(3):305-310. PubMed ID: 27320032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients.
    Roca B; Gómez CJ; Arnedo A
    J Infect; 2000 Jul; 41(1):50-4. PubMed ID: 10942640
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
    Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
    Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
    O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
    HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
    de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
    J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized controlled trial of a peer support intervention targeting antiretroviral medication adherence and depressive symptomatology in HIV-positive men and women.
    Simoni JM; Pantalone DW; Plummer MD; Huang B
    Health Psychol; 2007 Jul; 26(4):488-95. PubMed ID: 17605569
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study.
    Duran S; Solas C; Spire B; Carrieri MP; Fuzibet JG; Costagliola D; Lacarelle B; Moatti JP;
    AIDS; 2001 May; 15(8):1075-7. PubMed ID: 11399998
    [No Abstract]   [Full Text] [Related]  

  • 50. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
    Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G
    AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.
    Maggiolo F; Ravasio L; Ripamonti D; Gregis G; Quinzan G; Arici C; Airoldi M; Suter F
    Clin Infect Dis; 2005 Jan; 40(1):158-63. PubMed ID: 15614706
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Limitations of a simplification antiretroviral strategy for HIV-infected patients with decreasing adherence to a protease inhibitor regimen.
    Moya J; Casado JL; Aranzabal L; Moreno A; Antela A; Dronda F; Perez-Elías MJ; Marin A; Moreno S
    HIV Clin Trials; 2006; 7(4):210-4. PubMed ID: 17065033
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
    Røge BT; Barfod TS; Kirk O; Katzenstein TL; Obel N; Nielsen H; Pedersen C; Mathiesen LR; Lundgren JD; Gerstoft J
    HIV Med; 2004 Sep; 5(5):344-51. PubMed ID: 15369509
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load.
    Lepri AC; Miller V; Phillips AN; Rabenau H; Sabin CA; Staszewski S
    AIDS; 2001 Jan; 15(1):47-54. PubMed ID: 11192867
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Factors influencing antiretroviral therapy adherence among HIV-infected people on antiretroviral therapy in Ili Kazakh Autonomous Prefecture].
    Wang W; Liu W; Chen T; Liu NP; Zheng YJ; Ye SD; Zhang Y; Wang XM; Wang GZ; Zhang HB
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Feb; 51(2):160-164. PubMed ID: 28219156
    [No Abstract]   [Full Text] [Related]  

  • 57. HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.
    Pham QD; Huynh TK; Luong TT; Tran T; Vu TX; Truong LX
    HIV Clin Trials; 2013; 14(1):34-44. PubMed ID: 23372113
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Factors associated with adherence to antiretroviral therapy among HIV/AIDS patients in rural China.
    Wang X; Wu Z
    AIDS; 2007 Dec; 21 Suppl 8():S149-55. PubMed ID: 18172384
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.
    Masquelier B; Pereira E; Peytavin G; Descamps D; Reynes J; Verdon R; Fleury H; Garraffo R; Chêne G; Raffi F; Brun-Vézinet F;
    J Clin Virol; 2005 May; 33(1):75-8. PubMed ID: 15797369
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intention to adhere to HIV treatment: a patient-centred predictor of antiretroviral adherence.
    Nelsen A; Gupta S; Trautner BW; Petersen NJ; Garza A; Giordano TP; Naik AD; Rodriguez-Barradas MC
    HIV Med; 2013 Sep; 14(8):472-80. PubMed ID: 23551395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.